A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.

E M Brady et al.PubMed ↗Publisher ↗

What the trial testedas reported · 2014

Range includes no effect

No clear effect on cardiovascular events

4.1×1× to 17×

Bigger than almost all for cardiovascular events

As reported

OR 4.08, 95% CI 0.97–17.2

Not counted

Probably lowered glycemic control

−71%−81% to −59%

Bigger than 8 in 10 for glycemic control

As reported

IRR 0.29, 95% CI 0.19–0.41

Two numbers in the abstract

the abstract, start to end

… significance [odds ratio (OR) 4.08, 95% confidence interval (CI) …

… with liraglutide (incidence rate ratio 0.29, 95% CI 0.19, 0.41, …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

OR 4.080.97–17.2

Glycemic control

IRR 0.290.19–0.41

GLP-1 receptor agonistsSulfonylureas & glinidesGlycemic controlCardiovascular events

1 / 3

33 papers cite it

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it

The trial

NCT02694263phase 425 enrolled2016